Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific Sessions 2025 Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company's VK2735 obesity […]

Allison Transmission Announces Third Quarter 2025 Results

— Net Sales of $78 million in the Defense end market, up over 47% year over year — Net Income of $137 million, 19.8% of Net Sales — Achieved Adjusted EBITDA margin of 37% despite challenging demand environment — Net Cash Provided by Operating Activities of $228 million — Adjusted Free Cash Flow of $184

ROLLINS, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Double-Digit Revenue Growth Drives 20%+ EPS Growth and 30%+ Cash Flow Growth Rollins, Inc. (NYSE:ROL) (“Rollins” or the “Company”), a premier global consumer and commercial services company, reported unaudited financial results for the third quarter of 2025. https://mma.prnewswire.com/media/2257900/Rollins___Logo.jpg Key Highlights — Third quarter revenues were $1 billion, an increase of 12.0% over the third quarter

TDS and Array to release third quarter operating results and host conference call on November 7, 2025

Telephone and Data Systems, Inc. (NYSE: TDS) andArray Digital Infrastructure(NYSE:AD) will webcast their third quarter operating results conference call on November 7, 2025, at9:00 a.m. Central Time. The companies will release their financial results on November 7, 2025. To listen to the webcast, please visit the events & presentations pages of investors.tdsinc.comorinvestors.arrayinc.com. The presentation will

TROX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Tronox Holdings plc Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action – TROX

(NYSE:TROX), NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Tronox Holdings plc (NYSE: TROX) between February 12, 2025 and July 30, 2025, both dates inclusive (the “Class Period”), of the important November 3, 2025 lead plaintiff deadline. SO WHAT:

MGIC Investment Corporation Reports Third Quarter 2025 Results

Third Quarter 2025 Net Income of $191.1 million or $0.83 per Diluted Share Third Quarter 2025 Adjusted Net Operating Income (Non-GAAP) of $190.8 million or $0.83 per Diluted Share MGIC Investment Corporation (NYSE: MTG) today reported operating and financial results for the third quarter of 2025. Tim Mattke, CEO of MTG and Mortgage Guaranty Insurance

KLA Corporation Reports Fiscal 2026 First Quarter Results

— Total revenues were $3.21 billion, above the midpoint of the guidance range of $3.15 billion +/- $150 million; — GAAP diluted EPS was $8.47 and non-GAAP diluted EPS was $8.81, both above the midpoints of the respective guidance ranges; — Cash flow from operating activities for the quarter and last twelve months were $1.16

TROX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Tronox Holdings plc Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action – TROX

TROX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Tronox Holdings plc Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action – TROX GlobeNewswire October 29, 2025 NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Tronox

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

(NASDAQ:OPK), MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.

Giga Metals Completes First Tranche of Private Placement of Critical Minerals Flow-Through and Non-Flow-Through Units

(TSX-V:GIGA),(OTC US:GIGGF),(Other OTC:GIGGF),(Frankfurt:BRR2), NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) — Giga Metals Corp. (“Giga Metals” or the “Company”) (TSX-V: GIGA; OTCQB: GIGGF; FSE: BRR2) is pleased to announce that further to its news release dated October 15, 2025, the Company has

Scroll to Top